Teva announced the launch of Irbesartan and Irbesartan/Hydrochlorothiazide tablets, the generic versions of Bristol-Myers Squibb‘s Avapro and Avalide tablets.

Avapro is an angiotensin II receptor blocker that is indicated for hypertension and treatment of diabetic nephropathy in type 2 diabetes with hypertension. Avalide is a combination of an angiotensin II receptor blocker with a diuretic indicated for hypertension.

Irbesartan tablets are available from Teva in a 75mg dosage strength in 30- and 90-count bottles, and in 150mg and 300mg dosage strengths in 30-, 90-, and 500-count bottles. Combination Irbesartan and Hydrochlorothiazide tablets are available in 150mg/12.5mg and 300mg/12.5mg dosage strengths in 30- and 90-count bottles.

For more information call (888) TEVA-USA or visit